IL245281A0 - Methods and preparations for the treatment of cancer - Google Patents

Methods and preparations for the treatment of cancer

Info

Publication number
IL245281A0
IL245281A0 IL245281A IL24528116A IL245281A0 IL 245281 A0 IL245281 A0 IL 245281A0 IL 245281 A IL245281 A IL 245281A IL 24528116 A IL24528116 A IL 24528116A IL 245281 A0 IL245281 A0 IL 245281A0
Authority
IL
Israel
Prior art keywords
compositions
methods
treating cancer
cancer
treating
Prior art date
Application number
IL245281A
Other languages
English (en)
Hebrew (he)
Inventor
Jeffrey A Toretsky
Aykut Uren
Original Assignee
Univ Georgetown
Jeffrey A Toretsky
Aykut Uren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown, Jeffrey A Toretsky, Aykut Uren filed Critical Univ Georgetown
Publication of IL245281A0 publication Critical patent/IL245281A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/38Oxygen atoms in positions 2 and 3, e.g. isatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL245281A 2013-10-24 2016-04-21 Methods and preparations for the treatment of cancer IL245281A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361895308P 2013-10-24 2013-10-24
PCT/US2014/061418 WO2015061229A1 (en) 2013-10-24 2014-10-20 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
IL245281A0 true IL245281A0 (en) 2016-06-30

Family

ID=52993423

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245281A IL245281A0 (en) 2013-10-24 2016-04-21 Methods and preparations for the treatment of cancer

Country Status (11)

Country Link
US (2) US9511050B2 (enExample)
EP (1) EP3060207A4 (enExample)
JP (1) JP6389884B2 (enExample)
KR (1) KR20160065986A (enExample)
CN (1) CN105848654B (enExample)
AU (1) AU2014340398A1 (enExample)
CA (1) CA2927148A1 (enExample)
IL (1) IL245281A0 (enExample)
MX (1) MX2016004678A (enExample)
RU (1) RU2016114498A (enExample)
WO (1) WO2015061229A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232310B2 (en) * 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
ES2900243T3 (es) 2008-10-22 2022-03-16 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirimidina sustituidos como inhibidores de trk quinasa
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
MX2012013467A (es) 2010-05-20 2013-04-29 Array Biopharma Inc Compuestos macrociclicos como inhibidores de trk cinasa.
CA2869513C (en) 2012-04-12 2020-07-07 Georgetown University Methods and compositions for treating ewings sarcoma family of tumors
CA2927148A1 (en) * 2013-10-24 2015-04-30 Georgetown University Methods and compositions for treating cancer
CN107108580B (zh) 2014-10-09 2020-06-30 英克特诺治疗公司 吲哚酮化合物及其用途
US10799505B2 (en) 2014-11-16 2020-10-13 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
KR102277538B1 (ko) * 2015-06-08 2021-07-14 주식회사 대웅제약 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
DK3436434T3 (da) 2016-03-31 2020-09-21 Oncternal Therapeutics Inc Indolin-analoger og anvendelser deraf
HUE068971T2 (hu) 2016-04-04 2025-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
PT3800189T (pt) 2016-05-18 2023-07-27 Array Biopharma Inc Preparação de (s)-n-(5-((r)-2-(2,5- difluoropenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroxipirrolidina-1-carboxamida
US10761081B2 (en) * 2016-06-12 2020-09-01 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
US10613088B2 (en) * 2016-06-12 2020-04-07 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
MX395539B (es) 2016-07-29 2025-03-25 Oncternal Therapeutics Inc Usos de compuestos de indolinona
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN110431241B (zh) * 2017-02-28 2024-04-19 梅约医学教育与研究基金会 检测前列腺癌
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110845389A (zh) * 2019-10-17 2020-02-28 袁健 一种新型i型拓扑异构酶抑制剂
CN114057626B (zh) * 2021-12-07 2023-06-30 山东第一医科大学(山东省医学科学院) 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物
WO2026009227A1 (en) 2024-07-04 2026-01-08 Yeda Research And Development Co. Ltd. Compositions for downregulating zeb2 in macrophages and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483704D1 (de) 1983-07-22 1991-01-17 Du Pont Phenylchinolinsaeure und derivate als antitumormittel.
DE69922997T2 (de) * 1998-12-04 2005-12-15 Neurosearch A/S Verwendung von isatinderivaten als ionenkanalaktivierende mittel
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
AU2005323437B2 (en) 2004-04-30 2011-10-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a C5-modified pyrimidine
US20090217390A1 (en) 2005-04-29 2009-08-27 Fernando Lecanda Cordero Non-human animal sarcoma model
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
EP2124910A4 (en) * 2006-12-29 2012-02-15 Univ Georgetown ANTITUMOR THERAPY BY TARGETING EWS-FLI1
MX2009011281A (es) 2007-04-20 2010-03-08 Univ New York State Res Found Benzimidazol y composiciones farmaceuticas del mismo.
US20130259927A1 (en) * 2012-04-02 2013-10-03 Gradalis, Inc. Ewing's Sarcoma Bifunctional shRNA Design
CA2869513C (en) * 2012-04-12 2020-07-07 Georgetown University Methods and compositions for treating ewings sarcoma family of tumors
CA2927148A1 (en) * 2013-10-24 2015-04-30 Georgetown University Methods and compositions for treating cancer

Also Published As

Publication number Publication date
AU2014340398A1 (en) 2016-06-09
KR20160065986A (ko) 2016-06-09
US20170157089A1 (en) 2017-06-08
RU2016114498A3 (enExample) 2018-08-13
WO2015061229A1 (en) 2015-04-30
CA2927148A1 (en) 2015-04-30
MX2016004678A (es) 2017-03-10
CN105848654A (zh) 2016-08-10
CN105848654B (zh) 2018-10-02
JP6389884B2 (ja) 2018-09-12
US9511050B2 (en) 2016-12-06
EP3060207A4 (en) 2017-04-12
JP2016534084A (ja) 2016-11-04
US20160263086A1 (en) 2016-09-15
RU2016114498A (ru) 2017-11-29
EP3060207A1 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
IL281058B1 (en) Compositions and methods for treating anemia
IL245281A0 (en) Methods and preparations for the treatment of cancer
SMT201700595T1 (it) Composizioni e metodi per trattare il cancro
SG11201510751YA (en) Composition and vaccine for treating prostate cancer
EP3077049A4 (en) Compositions and methods for treating vitiligo
IL239921A0 (en) Preparations containing solutions in solid state and their use for the treatment of pain
IL244353A0 (en) Compounds and use for cancer treatment
SG11201508878WA (en) Methods of treating cancer
EP3004395A4 (en) Compositions and methods for treating cancer
EP3052102A4 (en) Compositions and methods for treating cancers
ZA201506330B (en) Methods and compositions for treating leukemia
SG10201710538XA (en) Compositions and methods for treating skin
PL3016682T3 (pl) Sposoby leczenia nowotworu
SG11201509596YA (en) Methods of treating cancer
EP2984185A4 (en) Methods and compositions for treating cancer
WO2014160368A9 (en) Compositions and methods for treating cancer
EP2841102A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER